(Q46900351)

26 December 2017

title

Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease (English)

1 reference

26 December 2017

positron emission tomography

1 reference

1 reference

1

Nicolaas I Bohnen

1 reference

26 December 2017

Roger L Albin

2

1 reference

26 December 2017

Robert A Koeppe

3

1 reference

26 December 2017

Kristine A Wernette

4

1 reference

26 December 2017

Michael R Kilbourn

5

1 reference

26 December 2017

Satoshi Minoshima

6

1 reference

26 December 2017

Kirk A Frey

7

1 reference

26 December 2017

publication date

18 January 2006

1 reference

26 December 2017

Journal of Cerebral Blood Flow & Metabolism

published in

1 reference

26 December 2017

volume

26

1 reference

26 December 2017

issue

9

1 reference

26 December 2017

page(s)

1198-1212

1 reference

26 December 2017

Slowing Parkinson's disease progression: recent dopamine agonist trials

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Initial agonist treatment of Parkinson disease: a critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Decreased striatal dopaminergic innervation in REM sleep behavior disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Cortical glucose metabolism in Parkinson's disease without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Functional identification and molecular cloning of a human brain vesicle monoamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Impact of psychostimulants on vesicular monoamine transporter function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Stereotaxic summation analysis of human cerebral benzodiazepine binding maps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Functional brain networks in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Dopamine visualized in the basal ganglia of living man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Diagnostic criteria for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

A voxel-based morphometric study of ageing in 465 normal adult human brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Synaptic vesicle phosphoproteins and regulation of synaptic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Marked disparity between age‐related changes in dopamine and other presynaptic dopaminergic markers in human striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Clinical trial end points: on the road to nowhere?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

In vivo radiotracers for vesicular neurotransmitter transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Comparison of methods for analysis of clinical [11C]raclopride studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Aging and Extrapyramidal Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Cerebral glucose metabolism in Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Pharmacology and regulation of the neuronal dopamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Striatal dopamine deficiency in Parkinson's disease: role of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

[3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

[3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Decreased dopamine transporters with age in health human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Evidence for cyclic AMP-mediated increase of aromatic L-amino acid decarboxylase activity in the striatum and midbrain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Decreased density of human striatal dopamine uptake sites with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Protein kinase A activity may kinetically upregulate the striatal transporter for dopamine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Regulation of DOPA decarboxylase activity in brain of living rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

The metabolic topography of parkinsonism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

A simple synthesis of [11C]dihydrotetrabenazine (DTBZ)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

The striatal transporter for dopamine in the rat may be kinetically up-regulated following 3 weeks of withdrawal from cocaine self-administration.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Membrane trafficking regulates the activity of the human dopamine transporter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

The vesicular monoamine transporter is not regulated by dopaminergic drug treatments

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600276

7 January 2021

Identifiers

DOI

10.1038/SJ.JCBFM.9600276

1 reference

26 December 2017

PubMed ID

16421508

1 reference

26 December 2017